Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Other Non Operating Income: 2014-2024

Historic Other Non Operating Income for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to $606,000.

  • Cartesian Therapeutics' Other Non Operating Income fell 101.71% to -$5,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $93,000, marking a year-over-year decrease of 90.62%. This contributed to the annual value of $606,000 for FY2024, which is 12.30% down from last year.
  • As of FY2024, Cartesian Therapeutics' Other Non Operating Income stood at $606,000, which was down 12.30% from $691,000 recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Other Non Operating Income registered a high of $691,000 during FY2023, and its lowest value of -$461,000 during FY2020.
  • Over the past 3 years, Cartesian Therapeutics' median Other Non Operating Income value was $606,000 (recorded in 2024), while the average stood at $542,333.
  • In the last 5 years, Cartesian Therapeutics' Other Non Operating Income skyrocketed by 2,100.00% in 2022 and then declined by 12.30% in 2024.
  • Cartesian Therapeutics' Other Non Operating Income (Yearly) stood at -$461,000 in 2020, then soared by 103.25% to $15,000 in 2021, then spiked by 2,100.00% to $330,000 in 2022, then surged by 109.39% to $691,000 in 2023, then declined by 12.30% to $606,000 in 2024.